Pharsight

Drugs that contain Sodium Oxybate

1. Lumryz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11052061 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US10952986 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US11602513 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US10272062 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US11000498 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US11400065 AVADEL CNS Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
Jul, 2037

(13 years from now)

US11826335 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US11839597 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US11065224 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US10973795 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US11504347 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US11602512 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US10736866 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US11766418 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US10925844 AVADEL CNS Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
Feb, 2040

(15 years from now)

US11583510 AVADEL CNS Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
Feb, 2042

(17 years from now)

US11779557 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Mar, 2042

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-431) May 01, 2030
New Product(NP) May 01, 2026

Market Authorisation Date: 01 May, 2023

Treatment: Treatment of a disorder treatable with gamma-hydroxybutyrate using a single, daily dose of a gamma-hydroxybutyrate formulation; Treatment of narcolepsy-related cataplexy or excessive daytime sleepines...

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

LUMRYZ family patents

Family Patents

2. Xyrem patents expiration

XYREM's oppositions filed in EPO
XYREM Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8263650 JAZZ PHARMS Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Dec, 2019

(4 years ago)

US9539330 JAZZ PHARMS Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Dec, 2019

(4 years ago)

US8324275 JAZZ PHARMS Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Dec, 2019

(4 years ago)

US8859619 JAZZ PHARMS Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Dec, 2019

(4 years ago)

US8952062 JAZZ PHARMS Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Dec, 2019

(4 years ago)

US7851506 JAZZ PHARMS Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Dec, 2019

(4 years ago)

US8324275

(Pediatric)

JAZZ PHARMS Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Jun, 2020

(3 years ago)

US8263650

(Pediatric)

JAZZ PHARMS Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Jun, 2020

(3 years ago)

US9539330

(Pediatric)

JAZZ PHARMS Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Jun, 2020

(3 years ago)

US8952062

(Pediatric)

JAZZ PHARMS Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Jun, 2020

(3 years ago)

US8859619

(Pediatric)

JAZZ PHARMS Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Jun, 2020

(3 years ago)

US7851506

(Pediatric)

JAZZ PHARMS Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Jun, 2020

(3 years ago)

US7262219 JAZZ PHARMS Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Jul, 2020

(3 years ago)

US6780889 JAZZ PHARMS Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Jul, 2020

(3 years ago)

US6780889

(Pediatric)

JAZZ PHARMS Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Jan, 2021

(3 years ago)

US7262219

(Pediatric)

JAZZ PHARMS Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Jan, 2021

(3 years ago)

US8457988 JAZZ PHARMS Sensitive drug distribution system and method
Dec, 2022

(1 year, 3 months ago)

US7895059 JAZZ PHARMS Sensitive drug distribution system and method
Dec, 2022

(1 year, 3 months ago)

US8589182 JAZZ PHARMS Sensitive drug distribution system and method
Dec, 2022

(1 year, 3 months ago)

US8731963 JAZZ PHARMS Sensitive drug distribution system and method
Dec, 2022

(1 year, 3 months ago)

US8731963

(Pediatric)

JAZZ PHARMS Sensitive drug distribution system and method
Jun, 2023

(9 months ago)

US8589182

(Pediatric)

JAZZ PHARMS Sensitive drug distribution system and method
Jun, 2023

(9 months ago)

US8457988

(Pediatric)

JAZZ PHARMS Sensitive drug distribution system and method
Jun, 2023

(9 months ago)

US7895059

(Pediatric)

JAZZ PHARMS Sensitive drug distribution system and method
Jun, 2023

(9 months ago)

US7765107 JAZZ PHARMS Sensitive drug distribution system and method
Jun, 2024

(2 months from now)

US7765106 JAZZ PHARMS Sensitive drug distribution system and method
Jun, 2024

(2 months from now)

US7668730 JAZZ PHARMS Sensitive drug distribution system and method
Jun, 2024

(2 months from now)

US7765106

(Pediatric)

JAZZ PHARMS Sensitive drug distribution system and method
Dec, 2024

(8 months from now)

US7765107

(Pediatric)

JAZZ PHARMS Sensitive drug distribution system and method
Dec, 2024

(8 months from now)

US7668730

(Pediatric)

JAZZ PHARMS Sensitive drug distribution system and method
Dec, 2024

(8 months from now)

US9486426 JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US8772306 JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US10213400 JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US11253494 JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US9050302 JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US10864181 JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US9050302

(Pediatric)

JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(9 years from now)

US11253494

(Pediatric)

JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(9 years from now)

US9486426

(Pediatric)

JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(9 years from now)

US8772306

(Pediatric)

JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(9 years from now)

US10213400

(Pediatric)

JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(9 years from now)

US10864181

(Pediatric)

JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Nov 18, 2012
Orphan Drug Exclusivity(ODE-231) Oct 26, 2025
New Patient Population(NPP) Oct 26, 2021
Pediatric Exclusivity(PED) Apr 26, 2026

Market Authorisation Date: 17 July, 2002

Treatment: Method of treating cataplexy in patients with narcolepsy; Method of treating excessive daytime sleepiness in patients with narcolepsy; Method of treating a patient with a prescription drug using a com...

Dosage: SOLUTION;ORAL

How can I launch a generic of XYREM before it's drug patent expiration?
More Information on Dosage

XYREM family patents

Family Patents